source
- Schrödinger launches Tectora Therapeutics with $55 million Series A to target immunology and inflammationSchrödinger announced the formation of Tectora Therapeutics, a new biotech focused on immune‑mediated diseases, backed by a $55 million Series A financing round. As part of the launch, Schrödinger…
- Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILDMosliciguat, the pulmonary hypertension candidate from Roivant Sciences subsidiary Pulmovant, cut pulmonary vascular resistance by more than 56% in a Phase 2 trial of patients with PH‑ILD, surpassi…